



EUROPEAN COMMISSION  
HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL  
Directorate G - Public Health, Luxembourg

## PUBLIC HEALTH APPLICATION FOR FUNDING

**European Commission**  
Directorate for Public Health and Safety at Work  
DG SANCO/G  
L-2920 LUXEMBOURG  
Fax: (352) 43.01.3.45.11

**To be completed by the Commission**

SAGA registration no:

\* Name of applicant organisation: **UNIT OF CANCER EPIDEMIOLOGY - CPO - PIEMONTE DEPT. OF ONCOLOGY - S. GIOVANNI A.S. HOSPITAL - AZIENDA SANITARIA LOCALE 1 TORINO**

\* Member State: **ITALY**

\* Name of project leader: **ANTONIO PONTI MD MPH**

\* Title of project: ***BREAST CANCER SCREENING EVALUATION DATABASE***

\* Reference of call for proposals:

\* Date of dispatch to the Commission: **October 2001**

**To enable us to deal with your dossier correctly, please indicate below the main subject area of this project (one cross at most)**

SANCO/G/2:  Cancer  
 Drug addiction  
 Pollution-related diseases

SANCO/G/3:  Health education and/or promotion, information and training in the field of public health  
 Prevention of accidents and injuries  
 Health surveillance

SANCO/G/4:  AIDS and other communicable diseases  
 Rare diseases

**N.B.**

*APPLICATIONS WHICH DO NOT COMPLY WITH THE FOLLOWING WILL BE REJECTED*

\*

Applications for funding must be submitted **in triplicate**

\*\*

Applications submitted by fax or e-mail **will not** be considered

\*\*\*

Applications must be **typewritten**

\*\*\*\*

Unsigned applications will be **rejected**

**An guide for applicants can be found at the end of the form**

## **PART ONE**

### **Administrative and budgetary information**

Mark a cross in the boxes which correspond exactly to your project

#### **FIELD OF ACTIVITY**

##### **SANCO/G/2**

- Cancer
- Drug addiction
- Pollution-related diseases

##### **SANCO/G/3**

- Health education and/or promotion
- Information and formation in the field of health
- Health surveillance
- Deliberate and accidental injuries and accidents outside the workplace

##### **SANCO/G/4**

- |  |   |
|--|---|
| <input type="checkbox"/> <b>AIDS and other communicable diseases</b> | <input type="checkbox"/> AIDS   |
|  | <input type="checkbox"/> Other communicable diseases                      |
|  | <input type="checkbox"/> Emerging diseases                                |
|  | <input type="checkbox"/> Surveillance network                             |
| <input type="checkbox"/> <b>Rare diseases</b>                        | <input type="checkbox"/> Establishment of European information network    |
|  | <input type="checkbox"/> Training and updating of professional skills     |
|  | <input type="checkbox"/> Promotion of transnational cooperation           |
|  | <input type="checkbox"/> Surveillance of rare diseases at Community level |

**TYPE OF PROJECT**

- |   |                                     |                                      |                                     |
|---|-------------------------------------|--------------------------------------|-------------------------------------|
| * Innovative approaches, pilot project, "model" project | <input checked="" type="checkbox"/> | * Creation and operation of networks | <input checked="" type="checkbox"/> |
| * Evaluation and review                                 | <input checked="" type="checkbox"/> | * Conference                         | <input type="checkbox"/>            |
| * Coordination of activity                              | <input type="checkbox"/>            | * Seminar                            | <input type="checkbox"/>            |
| * Feasibility studies                                   | <input type="checkbox"/>            | * Symposium                          | <input type="checkbox"/>            |
| * Communication   | <input type="checkbox"/>            |                                      |                                     |
| * Other ( <i>please specify</i> ): .....                |                                     |                                      | <input type="checkbox"/>            |
|   |                                     |                                      |                                     |
|   |                                     |                                      |                                     |

**METHODS**

- |   |                                     |  |                                     |
|---|-------------------------------------|--|-------------------------------------|
| * Primary prevention                        | <input type="checkbox"/>            | * Data collection                        | <input checked="" type="checkbox"/> |
| * Secondary prevention, including screening | <input checked="" type="checkbox"/> | * Training                               | <input type="checkbox"/>            |
|   | <input type="checkbox"/>            | * Epidemiology                           | <input checked="" type="checkbox"/> |
| * Care, special schemes                     | <input type="checkbox"/>            | * Prevention policy, health care systems | <input type="checkbox"/>            |
| * Social reintegration                      | <input type="checkbox"/>            | * Health education                       | <input type="checkbox"/>            |
| * Public information                        | <input type="checkbox"/>            |  |                                     |
| * Exchanges of information and experience   | <input checked="" type="checkbox"/> |  |                                     |
| * Other ( <i>please specify</i> ): .....    |                                     |  | <input type="checkbox"/>            |
|   |                                     |  |                                     |
|   |                                     |  |                                     |

*	Is the project complementary to a project previously supported by the Commission?	YES	<input checked="" type="checkbox"/>	NO	<input type="checkbox"/>
*	Is it a new project?	YES	<input type="checkbox"/>	NO	<input checked="" type="checkbox"/>
*	Are other partners involved? <b>If so, please turn to part 2 item 5</b>	YES	<input checked="" type="checkbox"/>	NO	<input type="checkbox"/>
*	What other Member States are involved?				
	<input type="checkbox"/> Austria		<input type="checkbox"/> Italy		
	<input checked="" type="checkbox"/> Belgium		<input checked="" type="checkbox"/> Luxembourg		
	<input type="checkbox"/> Denmark		<input type="checkbox"/> Netherlands		
	<input type="checkbox"/> Finland		<input type="checkbox"/> Portugal		
	<input checked="" type="checkbox"/> France		<input checked="" type="checkbox"/> Spain		
	<input checked="" type="checkbox"/> Germany		<input type="checkbox"/> Sweden		
	<input type="checkbox"/> Greece		<input type="checkbox"/> United Kingdom		
	<input type="checkbox"/> Ireland				
What other, non-member countries are involved?					
.....					
.....					
.....					

<b><u>PROPOSED TIMETABLE</u></b>	
*	Planned start of project: October 16, 2002
*	Duration of project (number of months):15 (December 31, 2003)

## GENERAL INFORMATION ON THE APPLICANT

Name of applicant: **ANTONIO PONTI MD MPH - CPO Piemonte**

- Name of legal representative: **AZIENDA SANITARIA LOCALE 1 - TORINO**

(**Dr. Mario Lombardo**)

\* Abbreviation: **ASL 1 TORINO**

\* Legal form: \* Public/quasi-public  \* Private  \*  
Non-profit-making

\* Address: \* Number/street: **CPO-Piemonte, 31, via S. Francesco da Paola**

\* Postcode: **10123** \* Town: **TORINO**

\* Country: **ITALY**

\* Tel. 1: **39 11 5664566** \* Tel. 2: **39 11 5664563**

\* Fax 1: **39 11 566 4561** \* Fax 2:

\* E-mail: [antonio.ponti@asl1.to.it](mailto:antonio.ponti@asl1.to.it)

\* Registration number:

\* Tax or VAT number: **P.I. C.F. 05437630014**

(*or proof of VAT exemption: see enclosure*)

\* Are you part of a European network? YES  Which? **EUROPEAN PILOT NETWORKS OF BREAST AND CERVICAL CANCER SCREENING**

NO

\* **Contractual representative of the project:**

- Surname: **LOMBARDO**

- Forename: **MARIO**

- Title: **DR.**

- Function: **DIRETTORE GENERALE**

- Telephone: **39 011- 5662241** - Fax: **39 011 5664561**

**Project leader:**

- Surname: **PONTI**

Forename: **ANTONIO**

- Title: **MD MPH**

- Function: **EPIDEMIOLOGIST**

- Telephone: **39 011 5664566-** Fax: **39 011 5664561**

### **BANK INFORMATION**

**Attach original of customer/account identification, i.e. a document from the bank giving the applicant's name and address, the name and address of the bank and the full bank account number**

- \* Name of the bank: **BANCA CASSA DI RISPARMIO DI TORINO**
- \* Abbreviation: **CRT**
- \* Branch: **AG. 38**
- \* Address: \* Number/street **48, CORSO TURATI**
  - \* Postcode: **10128** \* Town: **TORINO**
  - \* Country: **ITALY**
- \* Account number: **2039500/75**
- \* Bank code: **06320**
- \* SWIFT code: **CRTOITTT134**

### **PREVIOUS SERVICES/GRANTS**

Has the applicant already received grants from the Commission?

YES []

NO []

If YES:

Type and number of contract	Commission department	Year	Amount in Euro
SI2.318240 (2001CVG2-002)	EUROPE AGAINST CANCER	2000	51,935
SI2.307923 (2000CVG2-031)	EUROPE AGAINST CANCER	2000	73,587
SI2.129340 (99CVF2-015)	EUROPE AGAINST CANCER	2000	140,066
EL/2/98/5191/PI/IL.1.1A/FPC	EUROPE AGAINST CANCER	2000	10,300
SI2.144037 (99CVF2-033)	EUROPE AGAINST CANCER	1999	79,208
SI2.168540 (2000CVF2-002)	EUROPE AGAINST CANCER	1999	33,141
SOC102318;202433;200596; 200974;200967;200444	EUROPE AGAINST CANCER	1993-1998	276,770
SOC102319;202436;200595; 200678;200284;200263 92/CVV01115-0	EUROPE AGAINST CANCER	1993-1998	212,876
	EUROPE AGAINST CANCER	1992	11,000

-----  
**Please enclose a copy of the first page of the summary and the first page of the abstract of each final technical report submitted to the Commission**

## ESTIMATED BUDGET IN EURO

<u>EXPENDITURE</u>	<u>INCOME</u>
<b><u>DIRECT ELIGIBLE COSTS (D)</u></b>	
- Personnel costs 216,200 /	- Commission (funding requested) (S) <b>(maximum 70% of eligible costs)</b>
- Travelling and subsistence expenses: 34,617.52 /	<b>167,217.52 (65.5%) /</b>
- Miscellaneous services:  1,000 /	- Contribution pertaining to national officials /
- Administration  600 /	- Applicant's financial contribution (C) 88,200 /
- Reserve for unexpected costs 3,000 /	- Income generated by the project: (R)
	* Fees ...../
	* Document sales ...../
	* ...../
<b><u>INDIRECT ELIGIBLE COSTS (I)</u></b>	- Other external resources (R) (financial support already obtained)
- General costs ...../	* ...../
	* ...../
	* ...../
<b><u>CONTRIBUTION IN KIND (K)</u></b> (acceptable for calculating total cost)	- Other current funding applications (R)
- Unpaid voluntary work by physical person or legal entity: ...../	* ...../
	* ...../
- Contributions in kind essential to the implementation of the project: ...../	* ...../
	<b><u>CONTRIBUTION IN KIND (K)</u></b>
	...../
<b>GRAND TOTAL (D+I+K)</b>	<b>GRAND TOTAL (C+R+S+K)</b>
.....255,417.52...../	..... 255,417.52...../

## DETAILS OF ESTIMATED EXPENDITURE

<b><u>DIRECT ELIGIBLE COSTS: costs directly linked to the project (D)</u></b>	
<b>PERSONNEL COSTS</b>	
* <b>Fees</b> <i>(number of persons and functions x daily rate x number of days)</i>	
2 epidemiologists x 330 Euro x 70 days =	46,200
5 epidemiologists x 300 Euro x 20 days =	30,000
<b><u>(Florence, Germany, Strasbourg, Spain, Luxembourg)</u></b>	
2 research assistants x 120 Euro x 125 days =	30,000
1 software specialist x 250 Euro x 52 days =	13,000
1 datamanager x 150 Euro x 100 days =	15,000
5 research assistants x 200 Euro x 40 days =	40,000
<b><u>(Florence, Germany, Strasbourg, Spain, Luxembourg)</u></b>	
5 software specialists x 300 Euro x 20 days =	30,000
<b><u>(Florence, Germany, Strasbourg, Spain, Luxembourg)</u></b>	
<b>SUB-TOTAL : .....204,200...../</b>	
* <b>Personnel costs pertaining to national officials</b> <i>(function/number of persons x daily rate x number of days)</i>	
<b>SUB-TOTAL : ...../</b>	
<i>(to be indicated under "Income: contribution pertaining to national officials")</i>	
* <b>Secretarial costs:</b> <i>(number of persons x daily rate x number of days)</i>	
1 secretary x 120 Euro x 100 days =	12,000
<b>SUB-TOTAL : .....12,000...../</b>	
* <b>Other personnel costs:</b> <i>(number of persons and functions x daily rate x number of days)</i>	
<b>SUB-TOTAL : ...../</b>	
<b>TOTAL PERSONNEL COSTS .....216,200..... EURO</b>	

**TRAVEL/ACCOMMODATION/SUBSISTENCE**

**\* Travel expenses**

*(for each journey: purpose/means of transport/place of departure/destination/cost)*

**\* AIR**

**\* first expert meeting for update of evaluation database (two days)**

\* inner European trips to Turin x 700 Euro x 9 persons 6,300

**\* final meeting with Centres participating in data collection and experts (two days)**

\* inner European trips to Leuven x 700 Euro x 26 persons 18,200

\*

\*

\*

**SUB-TOTAL : .....24,500...../**

**\* Subsistence**

*purpose/place/number of days per trip x daily cost x number of persons)*

**\* first meeting**

\* 2 days x 9 persons x 129.82 Euro 2,336.76

**\* final meeting**

\* 2 days x 26 persons x 149.63 Euro 7,780.76

\*

\*

**SUB-TOTAL : .....10,117.52...../**

**TOTAL TRAVEL/SUBSISTENCE ....34,617.52... EURO**

**MISCELLANEOUS SERVICES**

- \* Information costs  
(e.g.: printing, computer support, conference programme, distribution)
- \* Printing software manuals and publication fees
- \*
- \*
- .....1,000...../
- \* Costs of reports/translation
- \*
- \*
- ...../
- \* Subcontracting
- \*
- \*
- \*
- ...../
- \* Interpreting costs
- \*
- \*
- \*
- ...../
- \* Audit/evaluation costs
- \*
- \*
- \*
- ...../
- \* Other services (please specify)
- \*
- \*
- ...../

**TOTAL MISCELLANEOUS SERVICES .....1,000..... EURO**

**PROJECT ADMINISTRATION**

\* Equipment  
(Purchase, rent or leasing)

\*

\*

...../

\* Purchase/rent of real estate

\*

\*

\*

...../

\* Cost of consumables and supplies directly necessary for project implementation  
(postage/telephone/fax/office supplies)

\* 40 special delivery mail x 15 Euro (corresp. to partic. Centres)      600

\*

.....**600**...../

\* Cost of financial services:  
(cost of banking transactions, insurance)

\*

\*

\*

...../

\* Cost of certificates/sureties  
(bank guarantee)

\*

\*

...../

**TOTAL PROJECT ADMINISTRATION .....600..... EURO**

**RESERVE FOR UNEXPECTED COSTS**

*Maximum 5% of direct eligible costs (personnel costs + travel/subsistence + miscellaneous services + project administration)*

- \*
- \*
- \*

**TOTAL RESERVE FOR UNEXPECTED COSTS ...3,000.0... EURO**

**INDIRECT ELIGIBLE COSTS (I)**

**INDIRECT COSTS (GENERAL)**

*Maximum 7% of total of personnel costs + travel/subsistence + miscellaneous services*  
**(Please list)**

- \*
- \*
- \*
- \*
- \*
- \*

**TOTAL INDIRECT ELIGIBLE COSTS .... EURO**

**CONTRIBUTION IN KIND (K)**  
**(but acceptable for calculating the total cost of the project)**

**\* Contributions in kind essential to the implementation of the project**  
*(e.g. rooms/translations/interpreting/social events)*

- \*
- \*
- \*
- \*
- \*
- \*

**\*Voluntary, unpaid work by a private individual (physical person or legal entity)**  
*(function/number of persons x daily rate x number of days)*

- \*
- \*
- \*
- \*
- \*
- \*

...../

*(amount to be indicated under “Income: contribution in kind by the applicant”, page 6)*

**GRAND TOTAL (D+I+K) ...255,417.52..... EURO**

**N.B.** : If these tables are too small, please provide appropriate tables based on the same model.

## **PART TWO**

### **Detailed description of the project**

**(In French, English or German if possible)**

**(Sections to be completed irrespective of field of activity)**

**N.B.** Do not write outside the boxes or add extra pages.

1) Statement of project aims

- To facilitate the implementation of the European Quality Assurance Guidelines in Mammography Screening (3<sup>rd</sup> edition, 2001) making available to all European breast cancer screening programmes a standard database and audit system capable of calculating, at a local or regional level, a number of process and early impact indicators of breast cancer screening specified in the same Guidelines.
- To merge data from participating screening programmes from several European Countries in this common database and perform a collective analysis of performance parameters from start of screening to the year 2000. Furthermore, to include data from screening programmes on a regional basis at least in one European country. This data collection represents a continuation and an extension of the one to be performed under the previous application round and allows to fully test and update the evaluation database

1. To acquire data useful for the updating of the European Guidelines.

2) How does your project relate to what has already been done in the field?

Funding during 2001-2002 allows to build the evaluation database and perform a first pilot analysis on one year of screening of data merged from participating centres. As for October 2001 the co-operation between the Turin and Leuven centres has allowed to build a pilot database, of which the description is enclosed, and to perform an analysis of data from the two programmes.

Several other projects conducted during recent years provide results and experiences that is being employed in conducting the present study. The European Guidelines on Quality Assurance in Mammography Screening, recently updated, define a number of performance and early impact parameters that each programme should monitor, with suggested targets. The European Breast Screening Network has performed a survey by questionnaire and collection of aggregated data, both co-ordinated in Luxembourg, directed to all breast cancer screening programmes within the Network and a number of site visits to the same programmes. Within the Network, the Leuven group is conducting a meta-analysis of screening data and the German group has co-ordinated and conducted particularly in Bremen and Weser-Ens the development of a comprehensive documentation system for mammography screening. The Luxembourg, Leuven and German groups bring their experiences as participants in this project and a close link will be maintained with the Euref co-ordinating office. National and local experiences also exist, which improve the likelihood of success of this project and may extend its potential impact. Study participants, from several European countries, will contribute their experiences in screening evaluation systems, of which two examples follow. The Florence group has promoted in Italy the definition of a minimum set of items needed to calculate the screening performance parameters. The regional screening programme in Piedmont, Italy (co-ordinated in Turin), has developed a regional screening evaluation datawarehouse capable to collect data from nine screening programmes and to allow calculation of performance parameters.

The European Guidelines on breast cancer screening include chapters on assessment and surgical treatment and on the collection of diagnosis and management data and suggest a minimum set of outcome measures in this area. An audit system, named QT, has been developed within the "Europe Against Cancer" programme with co-ordination by the Turin group and is now being widely used. The QT model is being used as a reference for this project and the screening evaluation database can be easily linked to QT, in a modular fashion.

### 3) Description of tasks/sequence of work/timetable

(This section must be completed with great care as it will be incorporated into the contract to be signed by the applicant if the project is approved)

1. Month 1-4. At the time the project starts, each participating Centre will have already available the screening evaluation database, built during the 2001-2002 project. The database will be updated in using the experience acquired during pilot testing. Data extraction in each participating Centre will concern the period from start of screening to the year 2000. It will be done under local responsibility and with assistance by the co-ordinating Centres. Participating Centres within the European Screening Network are: Turin and Florence (Italy), Leuven (Belgium), Luxembourg (Luxembourg), Cologne and Oldenburg (Germany) Strasbourg (France), Pamplona (Spain) and at least one Italian regional screening programme (including several local screening programmes) linked to the Italian Screening Network (GISMa). Each participating Centre will also encourage the distribution and use of the database on a regional/national basis.
2. Month 4-6. Data analysis and reporting will be performed locally using the standard reports available in the audit system. Performance parameters included in the European Screening Guidelines will be measured (compliance, detection rate, small cancers detection rates, benignant to malignant ratio, etc.) according to the evaluation design suggested in the same Guidelines (by first and subsequent screens, regular and irregualr, etc.) and strictly following the definitions stated there (for example on how to analyse intermediate mammographies or interval cancers). Parameters on interval cancers will be included in the analysis and Centres will be asked to briefly describe the methods used to collect such cases and to assess completeness.
3. Month 6-10. Data merge from participating Centres and common analysis and reporting. The assembling of a common database of anonymous data will be done in strict respect of european and national privacy regulations. Participants have confirmed that their participation is possible in respect of such regulations. The use of the assembled common database by any participating centre for research purposes will be clearly agreed upon and specified in a written protocol. The database will be also used by the Leuven group as one source for their meta-analysis project.
4. Month 10-15. Feed back and discussion of results among participants, involving experts from EUREF and the group who has edited and is periodically updating the European Screening Guidelines. This will be done also by means of a final meeting, devoted also to the discussion of results of the project on methanalysis of screening data lead by the Leuven group within the same Network.

**N.B.** Do not write outside the box

4) Applicant's ability to attain the objectives set

(Experience, facilities, etc.)

1. Curriculum vitae of the person responsible for the project (to be attached separately)
2. If the applicant is a corporate body, a copy of the document by which it was constituted (to be attached separately)
3. Brief description of the applicant body (aims, previous and current activities, etc.)

The Unit of Cancer Epidemiology of S.Giovanni A.S. Oncological Hospital, is organised in two sub-units: the Piedmont Cancer Registry and the Center for Evaluation and Organization of Cancer Screening. The Unit has been appointed as part of CPO (Centre for Cancer Prevention) of the Piedmont Region. The organisation and evaluation of the cervix uteri and breast cancer screening programmes for women resident in Turin are carried out by the Unit. The Unit has a staff of 19 persons with permanent positions, 9 of whom are epidemiologists. The epidemiologists are all medical doctors, 4 with post doctoral degree in epidemiology (at Harvard Univ. - USA, McGill Univ. (2) - Canada and Washington Univ., Seattle - USA), and 4 with postdoctoral degree in biostatistics (Biometric School of Milan Univ.). The research fields and the institutional activities are:- cancer registration - case-control studies on aetiology of melanomas and skin cancers - randomized trial on smoking cessation interventions - randomized trial on breast cancer screening in women aged 40-49 (Eurotrial) - randomized trial on breast cancer screening informed consent and compliance - breast and cervical cancer screening programmes organization - randomized controlled trial on HPV testing for cervical cancer - randomized controlled trial on the efficacy of rectosigmoidoscopic screening once in a lifetime - randomized trial for the evaluation of the impact of different strategies for colorectal cancer screening. The Turin Cervical and Breast Cancer Screening Programmes are members of the European Pilot Networks of Cancer Screening. The Unit, within the European Screening Network and with funding by the "Europe Against Cancer" programme, has developed the QT Audit System on breast cancer diagnosis and treatment, which is being used by Breast Units in several European Countries. The Unit is cooperating with the Dpt of Public Health and Social Medicine of the Erasmus Univ. in the Netherlands (mathematical models of screening outcomes), with the Centre for Research on Health Economics (CRESA) in Torino (economic evaluation), and with the Unit of Colorectal Cancer of the Imperial Cancer Research Fund (UK) on colorectal cancer screening. The Unit is also cooperating with the Memorial Sloane Kettering Cancer Centre of New York on a project on the genetics of skin melanoma and with the International Agency for Research on Cancer in Lyon for the estimate of the avoidable risk of skin cancer.

**N.B.** Do not write outside the box

5) Partnership: State name, address, telephone and fax numbers of bodies from other Member States taking part in the project

**Please attach a letter of intent from the partners attesting to their participation in the project**

- Belgium: LEUVEN  
**Erik Vanlimbergen, LUCK, Capucijnevoer 33, 3000 Leuven.**  
**Tel. + 32 16 346 900, + 32 16 346 907**
- France: STRASBOURG  
**Beatrice Gairard, ADEMAS, 69 Route du Rhin, BP314/67411 Illkirch.**  
**Tel. + 33 0390 40 59 30**
- Germany: COLOGNE, OLDENBURG  
**Larry vonKarsa, Mammographie-Screening Planungsstelle, Honinger Weg 115, 50969 Koln. Tel. + 49 221 4005 130**
- Italy: FLORENCE  
**Eugenio Paci, CSPO, 12 via di S.Salvi, 50135 Firenze. Tel. + 39 055 6263610**
- Luxembourg: LUXEMBOURG  
**Astrid Scharpantgen, CRP-Santé-Ministry of Health, 18 Rue Dicks, L - 1417 Luxembourg. Tel. + 352 478 55 63**
- Spain: PAMPLONA, VALENCIA  
**Nieves Ascunce Elizaga, Department of Health, Government of Navarra. Bergamin 2 bis, 31003 Pamplona. Tel. + 34 48 42 34 92**  
**Dolores Salas, Conselleria de Sanitat, Direccion General de Salud Publica, C/ Micer Masco 31, 46010, Valencia, 46020. Tel. + 34 96 3868051 (3869278)**

6) Community dimension and Community added value (please provide full details)

Screening Programmes from 6 members States participate in this project. The results will facilitate the recognition, in the respect of national diversities, of a common ground for the accreditation of excellence in screening. Data collected could facilitate future updating of european guidelines.

We expect to be able to show results of process performance parameters on an european scale and based on individual data, collected in such a way to privilege consistency and comparability. The database, periodically updated in item coding and outcome measures definitions according to most recent guidelines, should facilitate future analyses within european screening programmes electing to use it.

The computerised database and audit system should be an useful tool also at the local programme level and could be presented as a companion to the epidemiology chapter of the European Guidelines in order to facilitate their implementation and assist in measuring their impact.

7) Expected results of the project

The update and validation of a Quality Assurance tool (computerised audit system), available several European languages, to facilitate the implementation of European Quality Assurance Guidelines. Validation will include the use for screening evaluation in at least one Region-wide (multi-centre) screening programme. Screening programmes in all of Europe would be able to use a common database for evaluation of their results and for calculating European performance parameters.

Joint data collection of individual data from several European programmes, feed back to individual centres in order to improve quality and proposals for the updating of the guidelines.

**N.B.** Do not write outside the boxes

8) Assessment and follow-up of the project (provide details of funding expected for this activity at the end of the current project)

Within the European Network (executive board, annual meetings) and in connection with Eufef and the National Screening Networks (as GISMa in Italy). This would assure assessment and follow up of the project results at the end and also after the end of the funding period by the E.C.

9) Utilisation and dissemination of results among the scientific community and the general public

Results will be disseminated within the European Breast Screening Network and outside also by use of the Network and Eufef web sites. A final meeting for discussing the results will be organised. Papers will be published on peer-reviewed scientific journals.

10) Methods

- Update of a computerised database and audit system
- Multicenter data collection of individual data (in respect of privacy regulations)
- Analysis of performance parameters from each centre
- Feed back of results to participants
- Utilisation of experiences and results in the updating of the European Breast Screening Guidelines

**N.B.** Do not write outside the boxes

**Incomplete or incorrectly completed forms will be disregarded.**

If the application is accepted, the applicant undertakes to indicate on all documents resulting from the project (brochures, books, posters, etc.) that the project has received financial support from the European Commission.

\*\*\*\*\*

The applicant confirms that he is aware of all the conditions under which any Commission funding is granted.

The applicant solemnly declares that the information provided to the Commission in this document is true.

Date:

Signature of legal representative preceded by the words "Read and approved":

Name of signatory: